Novel modality share of oncology trials

Novel oncology modalities, especially cell and gene therapies, antibody-drug conjugates (ADCs), and multispecific antibodies, now account for 35% of oncology trials

The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.

Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.

APA

IQVIA Institute. (2024). Global Oncology Trends 2025. Retrieved September 16, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Via StatOrigin, https://statorigin.org/stat/stat_C1PEKQRJ2VB7SA84ZXAHP0ZQ03

Copy

MLA

IQVIA Institute. "Global Oncology Trends 2025." 2024, https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Accessed 16 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_C1PEKQRJ2VB7SA84ZXAHP0ZQ03.

Copy

Chicago

IQVIA Institute. "Global Oncology Trends 2025." 2024. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Accessed September 16, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_C1PEKQRJ2VB7SA84ZXAHP0ZQ03.

Copy

BibTeX

@misc{iqvia2024novelp0zq03, author = {{IQVIA Institute}}, title = {Global Oncology Trends 2025}, year = {2024}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_C1PEKQRJ2VB7SA84ZXAHP0ZQ03}, note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Accessed September 16, 2026.} }

Copy

Everything needed to check this number yourself, without taking our word for it.

Record last modified 17 September 2026. Value type: actual. Update cadence: annual. This page is permanently addressable at statorigin.org/stat/stat_C1PEKQRJ2VB7SA84ZXAHP0ZQ03.